FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283026857> ?p ?o ?g. }

• W4283026857 abstract "Abstract Background Listeriosis is a food-borne disease caused by the Gram-positive Bacillota (Firmicute) bacterium Listeria monocytogenes. Clinical L. monocytogenes isolates are often resistant to clinically used lincosamide clindamycin, thus excluding clindamycin as a viable treatment option. Objectives We have established newly developed lincosamide iboxamycin as a potential novel antilisterial agent. Methods We determined MICs of the lincosamides lincomycin, clindamycin and iboxamycin for L. monocytogenes, Enterococcus faecalis and Bacillus subtilis strains expressing synergetic antibiotic resistance determinants: ABCF ATPases that directly displace antibiotics from the ribosome and Cfr, a 23S rRNA methyltransferase that compromises antibiotic binding. For L. monocytogenes strains, either expressing VgaL/Lmo0919 or lacking the resistance factor, we performed time-kill kinetics and post-antibiotic effect assays. Results We show that the synthetic lincosamide iboxamycin is highly active against L. monocytogenes and can overcome the intrinsic lincosamide resistance mediated by VgaL/Lmo0919 ABCF ATPase. While iboxamycin is not bactericidal against L. monocytogenes, it displays a pronounced post-antibiotic effect, which is a valuable pharmacokinetic feature. We demonstrate that VmlR ABCF of B. subtilis grants significant (33-fold increase in MIC) protection from iboxamycin, while LsaA ABCF of E. faecalis grants an 8-fold protective effect. Furthermore, the VmlR-mediated iboxamycin resistance is cooperative with that mediated by the Cfr, resulting in up to a 512-fold increase in MIC. Conclusions While iboxamycin is a promising new antilisterial agent, our findings suggest that emergence and spread of ABCF ARE variants capable of defeating next-generation lincosamides in the clinic is possible and should be closely monitored." @default.
• W4283026857 created "2022-06-18" @default.
• W4283026857 creator A5001331353 @default.
• W4283026857 creator A5001868564 @default.
• W4283026857 creator A5048742125 @default.
• W4283026857 creator A5052041564 @default.
• W4283026857 creator A5058784218 @default.
• W4283026857 creator A5063795079 @default.
• W4283026857 creator A5081912852 @default.
• W4283026857 creator A5085940421 @default.
• W4283026857 date "2022-05-03" @default.
• W4283026857 modified "2023-10-14" @default.
• W4283026857 title "Synthetic oxepanoprolinamide iboxamycin is active against <i>Listeria monocytogenes</i> despite the intrinsic resistance mediated by VgaL/Lmo0919 ABCF ATPase" @default.
• W4283026857 cites W182661254 @default.
• W4283026857 cites W1980535030 @default.
• W4283026857 cites W1989960958 @default.
• W4283026857 cites W1996357595 @default.
• W4283026857 cites W2010168640 @default.
• W4283026857 cites W2018036788 @default.
• W4283026857 cites W2019644636 @default.
• W4283026857 cites W2026684460 @default.
• W4283026857 cites W2029860283 @default.
• W4283026857 cites W2038925439 @default.
• W4283026857 cites W2047162963 @default.
• W4283026857 cites W2060126442 @default.
• W4283026857 cites W2088188414 @default.
• W4283026857 cites W2097006899 @default.
• W4283026857 cites W2105838618 @default.
• W4283026857 cites W2110803333 @default.
• W4283026857 cites W2112259838 @default.
• W4283026857 cites W2114422486 @default.
• W4283026857 cites W2116764760 @default.
• W4283026857 cites W2121860020 @default.
• W4283026857 cites W2158447179 @default.
• W4283026857 cites W2158854420 @default.
• W4283026857 cites W2166117980 @default.
• W4283026857 cites W2166282078 @default.
• W4283026857 cites W2169152643 @default.
• W4283026857 cites W2214048066 @default.
• W4283026857 cites W2288396081 @default.
• W4283026857 cites W2315132400 @default.
• W4283026857 cites W2315609346 @default.
• W4283026857 cites W2342113215 @default.
• W4283026857 cites W2515150557 @default.
• W4283026857 cites W2560290738 @default.
• W4283026857 cites W2740577420 @default.
• W4283026857 cites W2770899020 @default.
• W4283026857 cites W2774722786 @default.
• W4283026857 cites W2785048017 @default.
• W4283026857 cites W2792557233 @default.
• W4283026857 cites W2800493509 @default.
• W4283026857 cites W2888642995 @default.
• W4283026857 cites W2911786618 @default.
• W4283026857 cites W2950693336 @default.
• W4283026857 cites W2985007500 @default.
• W4283026857 cites W3037260069 @default.
• W4283026857 cites W3091879679 @default.
• W4283026857 cites W3092766063 @default.
• W4283026857 cites W3168488117 @default.
• W4283026857 cites W3182036929 @default.
• W4283026857 cites W3207925895 @default.
• W4283026857 cites W3208116526 @default.
• W4283026857 cites W4200624925 @default.
• W4283026857 cites W4210361175 @default.
• W4283026857 cites W61590384 @default.
• W4283026857 doi "https://doi.org/10.1093/jacamr/dlac061" @default.
• W4283026857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35733912" @default.
• W4283026857 hasPublicationYear "2022" @default.
• W4283026857 type Work @default.
• W4283026857 citedByCount "4" @default.
• W4283026857 countsByYear W42830268572022 @default.
• W4283026857 countsByYear W42830268572023 @default.
• W4283026857 crossrefType "journal-article" @default.
• W4283026857 hasAuthorship W4283026857A5001331353 @default.
• W4283026857 hasAuthorship W4283026857A5001868564 @default.
• W4283026857 hasAuthorship W4283026857A5048742125 @default.
• W4283026857 hasAuthorship W4283026857A5052041564 @default.
• W4283026857 hasAuthorship W4283026857A5058784218 @default.
• W4283026857 hasAuthorship W4283026857A5063795079 @default.
• W4283026857 hasAuthorship W4283026857A5081912852 @default.
• W4283026857 hasAuthorship W4283026857A5085940421 @default.
• W4283026857 hasBestOaLocation W42830268571 @default.
• W4283026857 hasConcept C2777272437 @default.
• W4283026857 hasConcept C2777458120 @default.
• W4283026857 hasConcept C2778985905 @default.
• W4283026857 hasConcept C2779306812 @default.
• W4283026857 hasConcept C2779489039 @default.
• W4283026857 hasConcept C2779895986 @default.
• W4283026857 hasConcept C2780685696 @default.
• W4283026857 hasConcept C2781350384 @default.
• W4283026857 hasConcept C501593827 @default.
• W4283026857 hasConcept C523546767 @default.
• W4283026857 hasConcept C54355233 @default.
• W4283026857 hasConcept C86803240 @default.
• W4283026857 hasConcept C89423630 @default.
• W4283026857 hasConcept C94665300 @default.
• W4283026857 hasConceptScore W4283026857C2777272437 @default.
• W4283026857 hasConceptScore W4283026857C2777458120 @default.
• W4283026857 hasConceptScore W4283026857C2778985905 @default.
• W4283026857 hasConceptScore W4283026857C2779306812 @default.

• next